ID

39891

Description

Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir -Boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)- Naive Adults or Adults Recommencing ART.; ODM derived from: https://clinicaltrials.gov/show/NCT01258439

Link

https://clinicaltrials.gov/show/NCT01258439

Keywords

  1. 2/29/20 2/29/20 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

February 29, 2020

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility HIV NCT01258439

Eligibility HIV NCT01258439

  1. StudyEvent: Eligibility
    1. Eligibility HIV NCT01258439
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
provision of signed, informed consent
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
age >18 years
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
hiv infection documented by hiv antibody test and western blot prior to study entry
Description

HIV Infections | HIV Antibody Measurement | Western blot for HIV

Data type

boolean

Alias
UMLS CUI [1]
C0019693
UMLS CUI [2]
C3714540
UMLS CUI [3]
C0860963
no previous art or no art for 6 months prior to randomisation
Description

Antiretroviral therapy Absent

Data type

boolean

Alias
UMLS CUI [1,1]
C1963724
UMLS CUI [1,2]
C0332197
cd4+ count of <500 cells/mm or viral load >10,000 copies/ml within 60 days prior to randomisation
Description

CD4+ Count | Viral load measurement

Data type

boolean

Alias
UMLS CUI [1]
C0243009
UMLS CUI [2]
C1261478
no genotypic resistance to raltegravir, tenofovir/emtricitabine, darunavir, ritonavir
Description

Absence Resistance Genotypic Raltegravir | Absence Resistance Genotypic Tenofovir | Absence Resistance Genotypic Emtricitabine | Absence Resistance Genotypic Darunavir | Absence Resistance Genotypic Ritonavir

Data type

boolean

Alias
UMLS CUI [1,1]
C0332197
UMLS CUI [1,2]
C1514892
UMLS CUI [1,3]
C0017431
UMLS CUI [1,4]
C1871526
UMLS CUI [2,1]
C0332197
UMLS CUI [2,2]
C1514892
UMLS CUI [2,3]
C0017431
UMLS CUI [2,4]
C0384228
UMLS CUI [3,1]
C0332197
UMLS CUI [3,2]
C1514892
UMLS CUI [3,3]
C0017431
UMLS CUI [3,4]
C0909839
UMLS CUI [4,1]
C0332197
UMLS CUI [4,2]
C1514892
UMLS CUI [4,3]
C0017431
UMLS CUI [4,4]
C1435444
UMLS CUI [5,1]
C0332197
UMLS CUI [5,2]
C1514892
UMLS CUI [5,3]
C0017431
UMLS CUI [5,4]
C0292818
body mass index less than 30kg/m2
Description

Body mass index

Data type

boolean

Alias
UMLS CUI [1]
C1305855
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
primary hiv infection within the last 6 months
Description

Primary HIV infection Recent

Data type

boolean

Alias
UMLS CUI [1,1]
C1142553
UMLS CUI [1,2]
C0332185
active infection or opportunistic illness within the previous 30 days
Description

Communicable Disease Recent | Opportunistic Infection Recent

Data type

boolean

Alias
UMLS CUI [1,1]
C0009450
UMLS CUI [1,2]
C0332185
UMLS CUI [2,1]
C0029118
UMLS CUI [2,2]
C0332185
use of any medication contra-indicated with ritonavir-boosted darunavir or raltegravir
Description

Pharmaceutical Preparation Contraindicated Darunavir+Ritonavir | Pharmaceutical Preparation Contraindicated Raltegravir

Data type

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C1444657
UMLS CUI [1,3]
C1976853
UMLS CUI [2,1]
C0013227
UMLS CUI [2,2]
C1444657
UMLS CUI [2,3]
C1871526
use of lipid-lowering therapy
Description

Lipid-lowering therapy

Data type

boolean

Alias
UMLS CUI [1]
C0585943
diabetes mellitus (fasting glucose >7.0mml/l or a prior diagnosis of diabetes)
Description

Diabetes Mellitus | Glucose measurement, fasting

Data type

boolean

Alias
UMLS CUI [1]
C0011849
UMLS CUI [2]
C0202045
use of oral prednisolone > 7.5mg daily or equivalent
Description

Oral prednisolone U/day | Equivalent

Data type

boolean

Alias
UMLS CUI [1,1]
C0358513
UMLS CUI [1,2]
C0456683
UMLS CUI [2]
C0205163
pregnancy or breast feeding
Description

Pregnancy | Breast Feeding

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
proven hypersensitivity to one or more components of the study meal
Description

Hypersensitivity Component Study Meal

Data type

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C1705248
UMLS CUI [1,3]
C0008972
UMLS CUI [1,4]
C1998602

Similar models

Eligibility HIV NCT01258439

  1. StudyEvent: Eligibility
    1. Eligibility HIV NCT01258439
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Informed Consent
Item
provision of signed, informed consent
boolean
C0021430 (UMLS CUI [1])
Age
Item
age >18 years
boolean
C0001779 (UMLS CUI [1])
HIV Infections | HIV Antibody Measurement | Western blot for HIV
Item
hiv infection documented by hiv antibody test and western blot prior to study entry
boolean
C0019693 (UMLS CUI [1])
C3714540 (UMLS CUI [2])
C0860963 (UMLS CUI [3])
Antiretroviral therapy Absent
Item
no previous art or no art for 6 months prior to randomisation
boolean
C1963724 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
CD4+ Count | Viral load measurement
Item
cd4+ count of <500 cells/mm or viral load >10,000 copies/ml within 60 days prior to randomisation
boolean
C0243009 (UMLS CUI [1])
C1261478 (UMLS CUI [2])
Absence Resistance Genotypic Raltegravir | Absence Resistance Genotypic Tenofovir | Absence Resistance Genotypic Emtricitabine | Absence Resistance Genotypic Darunavir | Absence Resistance Genotypic Ritonavir
Item
no genotypic resistance to raltegravir, tenofovir/emtricitabine, darunavir, ritonavir
boolean
C0332197 (UMLS CUI [1,1])
C1514892 (UMLS CUI [1,2])
C0017431 (UMLS CUI [1,3])
C1871526 (UMLS CUI [1,4])
C0332197 (UMLS CUI [2,1])
C1514892 (UMLS CUI [2,2])
C0017431 (UMLS CUI [2,3])
C0384228 (UMLS CUI [2,4])
C0332197 (UMLS CUI [3,1])
C1514892 (UMLS CUI [3,2])
C0017431 (UMLS CUI [3,3])
C0909839 (UMLS CUI [3,4])
C0332197 (UMLS CUI [4,1])
C1514892 (UMLS CUI [4,2])
C0017431 (UMLS CUI [4,3])
C1435444 (UMLS CUI [4,4])
C0332197 (UMLS CUI [5,1])
C1514892 (UMLS CUI [5,2])
C0017431 (UMLS CUI [5,3])
C0292818 (UMLS CUI [5,4])
Body mass index
Item
body mass index less than 30kg/m2
boolean
C1305855 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Primary HIV infection Recent
Item
primary hiv infection within the last 6 months
boolean
C1142553 (UMLS CUI [1,1])
C0332185 (UMLS CUI [1,2])
Communicable Disease Recent | Opportunistic Infection Recent
Item
active infection or opportunistic illness within the previous 30 days
boolean
C0009450 (UMLS CUI [1,1])
C0332185 (UMLS CUI [1,2])
C0029118 (UMLS CUI [2,1])
C0332185 (UMLS CUI [2,2])
Pharmaceutical Preparation Contraindicated Darunavir+Ritonavir | Pharmaceutical Preparation Contraindicated Raltegravir
Item
use of any medication contra-indicated with ritonavir-boosted darunavir or raltegravir
boolean
C0013227 (UMLS CUI [1,1])
C1444657 (UMLS CUI [1,2])
C1976853 (UMLS CUI [1,3])
C0013227 (UMLS CUI [2,1])
C1444657 (UMLS CUI [2,2])
C1871526 (UMLS CUI [2,3])
Lipid-lowering therapy
Item
use of lipid-lowering therapy
boolean
C0585943 (UMLS CUI [1])
Diabetes Mellitus | Glucose measurement, fasting
Item
diabetes mellitus (fasting glucose >7.0mml/l or a prior diagnosis of diabetes)
boolean
C0011849 (UMLS CUI [1])
C0202045 (UMLS CUI [2])
Oral prednisolone U/day | Equivalent
Item
use of oral prednisolone > 7.5mg daily or equivalent
boolean
C0358513 (UMLS CUI [1,1])
C0456683 (UMLS CUI [1,2])
C0205163 (UMLS CUI [2])
Pregnancy | Breast Feeding
Item
pregnancy or breast feeding
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Hypersensitivity Component Study Meal
Item
proven hypersensitivity to one or more components of the study meal
boolean
C0020517 (UMLS CUI [1,1])
C1705248 (UMLS CUI [1,2])
C0008972 (UMLS CUI [1,3])
C1998602 (UMLS CUI [1,4])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial